RTP-026

DRUG2 trials

Sponsors

ResoTher Pharma A/S, ResoTher Pharma

Conditions

Patients with ST-Elevation Myocardial Infarction (STEMI)ST Elevation Myocardial Infarction

Phase 2

An exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026 to assess safety, tolerability, and efficacy in patients with ST-Elevation Myocardial Infarction (STEMI)

RecruitingCTIS2023-509182-21-00

ResoTher Pharma A/SPatients with ST-Elevation Myocardial Infarction (STEMI)

Start: 2024-09-16Target: 91Updated: 2025-11-24

A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)

RecruitingNCT06465303

ResoTher PharmaST Elevation Myocardial Infarction

Start: 2024-07-16End: 2025-12-21Target: 96Updated: 2025-09-22